



QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director,NHM, Shillong, East Khasi Hills Meghalaya, 793003 Shillong, 793003 MFG. LICENCE NO :		REPORT NO:EFRAC/2023/DRG/RG/03243ISSUE DATE:17/10/2023CUSTOMER REFERENCE:MailDATE:28/09/2023PAGE NO:1			
	SAM	PLE DETAILS	S		
SAMPLE REGISTRATION	I DETAILS				
Sample Name	: Cap Nifedipine 5mg	Sample Sample Batch S		e : 09/10/2023 n by : Client : N/A	
Sample Receipt Date	: 28/09/2023	Date o	f Expiry	: Jun-2025	
Registration No	: EFRAC/2023/DRG/RG/03243				
Name of Manufacturer	: N/A				
Batch No.	: MMDSL/QC-0001				
Date of Mfg.	: Jul-2023				
SAMPLE ANALYSIS DET	AILS				
Analysis Starting Date	: 17/10/2023	Analys	is Completion Date	e : 17/10/2023	3
		<u>EST RESULT</u>		1	
SL NO. TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

New co directo	D TO : Ilayan Medical Drugs And Serv Dony shillong, DHS, laitumkhr pr,NHM, Shillong, East Khasi Hi 9CENCE No :	ah, Office of the mission Ils Meghalaya, 793003	REPORT N ISSUE DAT CUSTOME DATE PAGE NO EST RESULT		EFRAC/2023/DRG/RG/0 17/10/2023 Mail 28/09/2023 2 of 3	3243
SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE		UOM 🦯	ACCEPTANCE LIMIT	RESULTS
	Identification	Indian Pharmacopoeia 2022	0	ŢĊ,	In the chromatogram obtained with the test solution the principal band appearing as a compact light orange band against a yellow background should correspond to that in the chromatogram obtained with reference solution (a). The band obtained with reference solution (b) appears as a single band under both visualisation procedure.	In the chromatogram obtained with the test solution the principal band appearing as a compact light orange band against a yellow background corresponds to that in the chromatogram obtained with reference solution (a). The band obtained with reference solution (b) appears as a single band under both visualisation procedure.
2	Disintegration test	Indian Pharmacopoeia 2022	-	Min./Sec.	NMT 30 Minutes	Min : 11 Min 43 Sec , Max : 12 Min 15 Sec
3	Dissolution Test	Indian Pharmacopoeia 2022	5 mg/Cap	% of L.C.	NLT 75.0	Avg : 96.28 , Min : 90.10 , Max : 100.03
4	Uniformity of the weight	Indian Pharmacopoeia 2022	-	%	(±) 7.5	Avg wt : 271.08 mg , (-) Dev : 4.7 , (+) Dev : 4.4
5	Assay	Indian Pharmacopoeia 2022	5 mg/Cap	% of L.C.	4.5 to 5.5 mg/Cap i.e. 90.0 - 110.0	4.97 mg/Cap i.e. 99.37









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director,NHM, Shillong, East Khasi Hills Meghalaya, 793003 Shillong, 793003 MFG, LICENCE No :	REPORT NO ISSUE DATE CUSTOMER REFERENCE DATE PAGE NO	 EFRAC/2023/DRG/RG/03243 17/10/2023 Mail 28/09/2023 3 of 3 	
In the opinion of the undersigned, the Sample referred to above as defined in the Act or the Rules madethere under for the reasor		not of Standard Quality	-

- Date : 17/10/2023
- UOM : Unit of Measurement
- REMARKS : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the results obtained for tested parameters only.
- Note : This Report is valid only for use in Indian (Domestic) Market & is Not valid for use in any International Market.

LE

-END OF THE TEST REPORT-



